Fig. 3.

AZD9496 effect in endocrine-resistant ER +  cells. a Immunoblot for ER and downstream ER targets PR and BCL2 in MCF7 and T47D parental (P) and endocrine-resistant models (EDR, TamR, and FulR). b, c Effect of different endocrine therapies, all in ED-medium, ED, tamoxifen 10^–7 M (Tam), fulvestrant 10^–7 M (Ful), and AZD9496 10^–7 M (9496), on the growth of resistant cell models: MCF7 EDR, TamR, and FulR (b); T47D EDR, TamR, and FulR (c). Cell viability is expressed as relative percentage compared to its own control (hatched bars; EDR to ED, TamR to Tam, and FulR to Ful) at day 6 of treatment. SEM are shown (n = 3); *p < 0.05; ***p < 0.001; ****p < 0.0001